Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · Real-Time Price · USD

3.600

-0.060 (-1.64%)

Oct 2, 2026, 4:00 PM EDT - Market closed

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	11.33	3.5	3.86	4.09	5.4	44.44
Short-Term Investments	206.4	89.51	41.05	92.23	142.93	167.47
Cash & Short-Term Investments	217.73	93.01	44.91	96.32	148.32	211.91
Cash Growth	955.95%	107.10%	-53.38%	-35.06%	-30.01%	80.98%
Other Receivables	0.01	-	-	-	0.51	0.09
Receivables	0.01	-	-	-	0.51	0.09
Prepaid Expenses	1.3	0.98	0.89	1.19	4.04	11.3
Total Current Assets	219.04	93.98	45.8	97.51	152.87	223.3
Other Long-Term Assets	0.02	0.02	0.02	0.04	0.03	0.03
Total Assets	219.06	94	45.82	97.55	152.91	223.33

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.41	1.57	4.13	3.51	5.26	11.19
Accrued Expenses	5.01	4.86	6.16	8.69	7.21	3.87
Total Current Liabilities	7.42	6.43	10.29	12.19	12.47	15.06
Other Long-Term Liabilities	5.08	1.06	0	-	-	-
Total Liabilities	12.5	7.49	10.3	12.19	12.47	15.06

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.11	0.07	0.03	0.03	0.03	0.03
Additional Paid-In Capital	936.68	784.71	676.37	646.23	602.52	513.3
Retained Earnings	-730.23	-698.27	-640.88	-560.9	-462.11	-305.07
Shareholders' Equity	206.56	86.51	35.52	85.36	140.44	208.26
Total Liabilities & Equity	219.06	94	45.82	97.55	152.91	223.33

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Cash (Debt)	217.73	93.01	44.91	96.32	148.32	211.91
Net Cash Growth	955.95%	107.10%	-53.38%	-35.06%	-30.01%	80.98%
Net Cash Per Share	2.97	2.36	1.49	3.20	5.01	12.07
Filing Date Shares Outstanding	106.67	104.89	33.19	30.17	30.1	29.37
Total Common Shares Outstanding	106.67	73.33	30.1	30.1	30.1	27.74
Working Capital	211.62	87.55	35.5	85.31	140.4	208.24
Book Value Per Share	1.94	1.18	1.18	2.84	4.67	7.51
Tangible Book Value	206.56	86.51	35.52	85.36	140.44	208.26
Tangible Book Value Per Share	1.94	1.18	1.18	2.84	4.67	7.51

SEC Filings: 10-K · 10-Q